Article

Epigenetic biomarkers for clinical outcomes and mechanisms driving emergence of drug resistance in ovarian cancer

2017-01-01

Abstract excerpt

Epithelial ovarian cancer (EOC) has a poor prognosis, with a 5 year survival rate of ~40%. A major therapeutic barrier is disease chemoresistant to the standard therapeutic regimen of taxol and platinum. Efficacious therapies in chemoresistant disease, a fuller understanding of the molecular mechanisms driving tumour evolution, and drugs to prevent emergence of chemoresistance are required. Bevacizumab, a VEGF inh...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b0b093f4-fd04-5fe7-a00c-2332460f57f9
DOI: 10.25560/54847

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Epigenetic biomarkers for clinical outcomes and mechanisms driving emergence of drug resistance in ovarian cancerDOI 10.25560/54847Read

The genomic landscape of recurrent ovarian high grade serous carcinoma: the BriTROC-1 studySemantic proximity Read

Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience.Semantic proximity Read

Tracking clonal evolution of drug resistance in ovarian cancer patients by exploiting structural variants in cfDNASemantic proximity Read

Next‐generation sequencing unravels extensive genetic alteration in recurrent ovarian cancer and unique genetic changes in drug‐resistant recurrent ovarian cancerSemantic proximity Read

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaSemantic proximity Read

DNA Methylation and Transcriptomic Features are Preserved Throughout Disease Recurrence and Chemoresistance in High Grade Serous Ovarian CancersSemantic proximity Read

The discovery and evaluation of treatment stratification biomarkers in epithelial ovarian cancerSemantic proximity Read

Distinct genomic profiles are associated with treatment response and survival in ovarian cancerSemantic proximity Read

Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancerSemantic proximity Read

Epigenetic biomarkers in epithelial ovarian cancer.Semantic proximity Read

Unveiling the epigenomic mechanisms of acquired platinum‐resistance in high‐grade serous ovarian cancerSemantic proximity Read

Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathwaysSemantic proximity Read